Receiving an electronic reminder about influenza vaccination appeared to decrease COVID vaccination rates. Further study of ...

Quarterly Net Profit at Rs. 91.30 crore in December 2024 down 33.7% from Rs. 137.70 crore in December 2023. EBITDA stands at ...

Sanofi adopts US FDA-selected flu strains to ensure readiness for the 2025-26 flu season: Bridgewater, New Jersey Monday, March 17, 2025, 14:00 Hrs [IST] Sanofi announced the imme ...

Latigo Biotherapeutics has whipped together a $150 million series B fundraising round to advance a pipeline of non-opioid ...

Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the manufacturing and delivery of its vaccine portfolio for the 2025 ...

Latigo Biotherapeutics ("Latigo"), a clinical-stage biotechnology company developing best-in-class non-opioid pain treatments ...

Sanofi (SNY) announced the immediate adoption of influenza strains selected by the Food and Drug Administration to advance the manufacturing ...

Sanofi stock is surging with a Golden Cross formation and promising Dupixent results. With FDA review and potential approval, investors are excited.

Twice-daily application of ruxolitinib cream demonstrated an ability to reduce itching and blistering in prurigo nodularis, a ...

Regeneron Pharmaceuticals, Inc. faces Eylea revenue decline but shows growth potential with Dupixent & Libtayo. Click for ...

Attorney General Aaron M. Frey announced a settlement agreement with Sanofi-Aventis U.S. LLC after scrutiny over the ...